Table 1.
Fold of Change | ||
---|---|---|
Subpathway | Biochemical Name | PCB126 vs. VEH |
Medium chain fatty acid | Caproate (6: 0) | 1.967 |
5-Dodecenoate (12: 1n7) | 1.1949 | |
Long chain fatty acid | Myristate (14: 0) | 1.6483 |
Myristoleate (14: 1n5) | 1.5047 | |
Pentadecanoate (15: 0) | 1.3333 | |
Palmitate (16: 0) | 1.4202 | |
Palmitoleate (16: 1n7) | 1.689 | |
Margarate (17: 0) | 1.8135 | |
10-Heptadecenoate (17: 1n7) | 2.1296 | |
Stearate (18: 0) | 1.3224 | |
Oleate/vaccenate (18: 1) | 1.8901 | |
Nonadecanoate (19: 0) | 1.7897 | |
10-Nonadecenoate (19: 1n9) | 2.4285 | |
Arachidate (20: 0) | 2.1044 | |
Eicosenoate (20: 1) | 3.4008 | |
Behenate (22: 0)* | 1.4465 | |
Erucate (22: 1n9) | 2.8541 | |
Nervonate (24: 1n9)* | 1.3063 | |
Polyunsaturated fatty acid (n3 and n6) | Heneicosapentaenoate (21: 5n3) | 3.933 |
Hexadecadienoate (16: 2n6) | 2.2067 | |
Stearidonate (18: 4n3) | 1.5706 | |
Eicosapentaenoate (EPA; 20: 5n3) | 1.2174 | |
Docosapentaenoate (n3 DPA; 22: 5n3) | 1.985 | |
Docosahexaenoate (DHA; 22: 6n3) | 1.2193 | |
Docosatrienoate (22: 3n3) | 2.5254 | |
Nisinate (24: 6n3) | 1.211 | |
Linoleate (18: 2n6) | 1.835 | |
Linolenate [alpha or gamma; (18: 3n3 or 6)] | 1.8176 | |
Dihomo-linolenate (20: 3n3 or n6) | 2.5076 | |
Arachidonate (20: 4n6) | 1.1887 | |
Adrenate (22: 4n6) | 1.3929 | |
Docosapentaenoate (n6 DPA; 22: 5n6) | 1.3923 | |
Docosadienoate (22: 2n6) | 2.6117 | |
Dihomo-linoleate (20: 2n6) | 3.0053 | |
Mead acid (20: 3n9) | 1.2317 | |
Docosatrienoate (22: 3n6)* | 1.8835 | |
Fatty acid, branched | 15-Methylpalmitate (i17: 0) | 1.5624 |
17-Methylstearate (i19: 0) | 1.7984 |
Hepatic fatty acid methyl esters were quantitated and significant differences were determined by Welch’s two-sample t-tests. Red shading and bold values denotes significantly increased lipid abundance in PCB 126-treated mice (fold change compared to Vehicle; p < .05).